Indian Journal of Science and Technology

Open Access Open Access  Restricted Access Subscription Access

The Physiological Alterations Induced by Sibutramine Anti-Obesity Drug on the Functions of the Thyroid Gland and the Liver: An Experimental Study on Wistar Rats


Affiliations
1 King Abdul Aziz University, PO box-19230, Jeddah 21435, Saudi Arabia
 

The present study investigates the safety of Sibutramine anti-obesity drug on the thyroid gland functions as well as the liver functions in adult male Wistar rats. A set of animals were treated with a daily dose of (7 mg/Kg) of Sibutramine for 2 weeks (second group: G II). While, another set were treated with the same dose for 6 weeks (third group: G III), At the end of each treatment periods, the serum parameters were measured (TT3, TT4, cortisol, ALT, AST, ALP&total bilirubin). Significant increases were recorded in means of TT3 and cortisol (1.78±0.025 ng/dl and 8.39±0.53 μg/l respectively) was recorded in the third group (G III) compared to the control group (t-Test, P≤0.05 and P≤0.01 respectively). In addition, highly significant decrease was observed in TT4 (1.98 ±0.06 μg/dl) (t-Test, P≤0.01). Similarly, highly significant increases was observed in the liver enzymes (ALT, AST&alkaline phosphatase) (184.42±11.60, 263.16±16.20 & 116.28±9.54 IU/l respectively) (t-Test, P≤0.01). Also, significant increase was recorded in the total bilirubin (0.65±0.03 mg/dl) (t-Test, P≤0.05). The present study clearly showed that the long use of Sibutramine is responsible for inducing serious physiological adverse effects on the thyroid gland functions as well as on the liver functions. Therefore, it can be concluded that the long use of Sibutramine is not therapeutically safe. In addition, it is recommended at the end of this study that Sibutramine should not be prescribed at all for any patient who has a history of hormonal or liver disorders.

Keywords

Sibutramine, Anti-Obesity Drug, Thyroid Gland, Liver Functions, Rat
User

  • Aberle J, Freier A, Busch P, Beil F and Dannheim Vand Mann O (2009) Treatment with Sibutramine prior to Roux-en-Y gastric bypass leads to an improvement of metabolic parameters and to a reduction of liver size and operative time. J. Obesity Surgery. 19(11), 1504-1507.

  • Amundsen MO, Engdahl B, Berg C and Nordeng H (2010) Cardiovascular co-medication among users of anti-obesity drugs: A population based study. J. Pharm. World Sci. PubMed indexed no. 20740723.

  • Astrup A (2010) Drug management of obesity efficacy versus safety. New Eng. J. Med. 63(3), 288-293.

  • Batty D and Czernichow S (2010) Withdrawal of Sibutramine for weight loss: Where does this leave clinicians? J. Obesity Facts. 3(3), 155-158.

  • Chounta A, Tsiodras S, Zouridakis S, Doumas M and Gamarello H (2005) Sibutramine use associated with reversible hepatotoxicity. Annals Internal Med. 143, 763- 768.

  • Chudasama HR and Bhatt PA (2009) Evaluation of antiobesity activity of duloxetine in comparison with sibutramine along with its anti-depressant activity: An experimental study in obese rats. Can. J. Physiol. Pharmacol. 87(11), 900-907.

  • Coletta DK, Bates SH, Jones RB and Bailey CJ (2006) The sibutramine metabolite M2 improves glucose uptake and reduces hepatic glucose output: Preliminary data. Diab. Vascular Diseases Res. J. 3(3), 186-188.

  • Eroglu E, Gemici G, Bayrak F, Kalkan A and Degertekin M (2009) Acute myocardial infarction in a 24 years old man possibly associated with Sibutramine use. Int. J. Cardiology. 137(2), 43-47.

  • Halford JC, Harrodld JA, Lawton CL and Blundell JE (2005) Serotonin (5-H) drugs: Effects on appetite expression and use for treatment. J. Curr. Drug Targets. 6(2), 201-213.

  • Hansen H, Hansen G, Tang-Christensen M, Axel A, Raben A and Mikkelsen J (2010) The novel triple monoamine reuptake inhibitor tesofensine induce sustained weight loss and improves glycemic control in the diet-induced obese rats comparison to sibutramine and Rimonabant. Euro. J. Pharmacol. 636(1-3), 88-95.

  • Harrison W, Ashton J and Herbison P (2010) Fatal and non-fatal cardiovascular events in a general population prescribed Sibutramine in New Zealand: A prospective cohort study. J. Drug Safety. 33(7), 605-613.

  • Horie N, Cercato C, Manicni M and Halpern A (2010) Long-term pharmacotherapy for obesity in elderly patients: A retrospective evaluation of medical records from specialized obesity outpatient clinic. J. Drugs Aging. 27(6), 497-506.

  • James WP, Caterson ID, Coutinho W, Sharma AM, Rode RA and Renz CL (2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. New England J. Med. 263(10), 905-917.

  • Keskin L, Sahin I, Bentil R and Senel S (2006) The effects of orlistat and sibutramine on some thyroid hormones levels in obese subjects. Endocrin. Abst. J. 11853-861.

  • Link M, Novotna R, Suchanova B, Skalova L, Wsol V and Szotakova B (2010) The stereo-selective biotransformation of anti-obesity drug sibutramine in rat liver microsomes and in cultures of rat hepatocytes. J. Pharmacy Pharmacol. 76 (1), 245-255.

  • Luisa DA, Allerb R, Izaolaa O, Condea R and Gonzalezb J (2008) Transaminases nonalcoholic fatty liver disease patients, relation with insulin resistance. J. Diabetes Res. Clinical Practices. 79(1), 74-78.

  • Luque CA and Rey JA (1999) Sibutramine a serotonin– norepinephrine reuptake inhibitor for treatment of obesity. Ann. Pharmacotherapy. 33(9) 968-978.

  • Luque CA and Rey JA (2002) The discovery and status of sibutramine as an antiobesity drug. Euro. J. Pharmacol. 440(2-3), 119-128.

  • McMahon F, Weinstein S, Rowe E, Ernst K and Fujioka K (2002) Sibutramine is a safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzymes inhibitors. J. Hum. Hypertens. 16(1), 5-11.

  • McTigue K, Harris R, Hemphill M, Lux LJ, Sutton S and Lohr K (2003) Screening and intervention for overweight and obesity in adults. PubMed. indexed 20803315.

  • Mo SL, Liu YH, Duan W, Kanwar JR and Zhou SF (2009) Substrate specificity, regulation and polymorphism of human cytochrome P450 2B6. J. Curr. Drug Metabolism. 10(7), 730-753.

  • Nisoli E and Carrubo M (2003) A benefits-risks assessment of Sibutramine in the management of obesity. J. Drug Safety. 26(14), 1027-1048.

  • Oh S, Kim K, Chung Y and Shong M (2009) Anti-obesity agents: A focused review on the structural classification of therapeutic entities. J. Curr. Med. Chem. 9(6), 466- 481.

  • Pagotto U, Vanuzzo D, Vicennati V and Pasquali R (2008) Pharmacological therapy of obesity. Italian Cardiol. J. 9(4), 835-935.

  • Panigrahi T, Panigrahi S, Wiechec E and Los M (2009) Obesity: Pathophysiology and clinical management. J. Curr. Med. Chem. 16(4), 506-521.

  • Ryan D, Kaiser P and Bray G (1995) Sibutramine: A novel new agent for obesity treatment. J. Obesity Res. 3(4), 553-559.

  • Scheen AI (2010) Cardiovascular risk-Benefits profile of sibutramine. Amer. J. Cardiovascul. Drugs. 10(5), 312- 334.

  • Sharma AM, Gaal LV, Finer NT, James P, Bacher P and Torp-Pedersen C (2008) Tolerability of sibtramine during a 6 weeks treatment period in high-risks patients with cardiovascular outcomes trial. J. Cardiovascular Pharmacol. 52(5), 393-402.

  • Smith B, Thomsen W and Grottick A (2006) The potential use of selective 5-HT2C agoiists in treating obesity. J. Expt. Invest. Drugs. 15(3), 257-266.

  • Smith S, Waggoner A, De las Fuentes L and Davil- Roman V (2009) Role of Serotoninergic pathway in drug induced valvular heart disease and diagnostic features by echocardiography. J. Am. Soc. Echocardiography. 22(8), 883-889.

  • Solomon K, Gooch S and Wong A (2005) Toxicity with selective serotonin reuptake inhibitors. Amer. J. Psychiatry. 162(6), 1225-1230.

  • Strano-Rossi S, Colamonici C and Botre F (2006) Delectation of sibutramine administration: A gas chematography/mass spectrometry study of the main urinary metabolites. J. Rapid Commun. Mass Spectrometery. 21(2), 79-88.

  • Tallett AJ, Blundell JE and Rodgers RJ (2008) Sibtramine induced anorexia: Potent, dose-dependent and behaviorally selective profile in male rats. Behavioral Brain Res. 213-221.

  • Viner RM, Hsia Y, Neubert A and Wong IC (2009) Rise in anti-obesity drug prescribing for children and adolescents in the UK: A population based study. British J. Clin. Pharmacol. 68(6), 844-851.


Abstract Views: 457

PDF Views: 132




  • The Physiological Alterations Induced by Sibutramine Anti-Obesity Drug on the Functions of the Thyroid Gland and the Liver: An Experimental Study on Wistar Rats

Abstract Views: 457  |  PDF Views: 132

Authors

Ameen Saleh Bin Bisher
King Abdul Aziz University, PO box-19230, Jeddah 21435, Saudi Arabia

Abstract


The present study investigates the safety of Sibutramine anti-obesity drug on the thyroid gland functions as well as the liver functions in adult male Wistar rats. A set of animals were treated with a daily dose of (7 mg/Kg) of Sibutramine for 2 weeks (second group: G II). While, another set were treated with the same dose for 6 weeks (third group: G III), At the end of each treatment periods, the serum parameters were measured (TT3, TT4, cortisol, ALT, AST, ALP&total bilirubin). Significant increases were recorded in means of TT3 and cortisol (1.78±0.025 ng/dl and 8.39±0.53 μg/l respectively) was recorded in the third group (G III) compared to the control group (t-Test, P≤0.05 and P≤0.01 respectively). In addition, highly significant decrease was observed in TT4 (1.98 ±0.06 μg/dl) (t-Test, P≤0.01). Similarly, highly significant increases was observed in the liver enzymes (ALT, AST&alkaline phosphatase) (184.42±11.60, 263.16±16.20 & 116.28±9.54 IU/l respectively) (t-Test, P≤0.01). Also, significant increase was recorded in the total bilirubin (0.65±0.03 mg/dl) (t-Test, P≤0.05). The present study clearly showed that the long use of Sibutramine is responsible for inducing serious physiological adverse effects on the thyroid gland functions as well as on the liver functions. Therefore, it can be concluded that the long use of Sibutramine is not therapeutically safe. In addition, it is recommended at the end of this study that Sibutramine should not be prescribed at all for any patient who has a history of hormonal or liver disorders.

Keywords


Sibutramine, Anti-Obesity Drug, Thyroid Gland, Liver Functions, Rat

References





DOI: https://doi.org/10.17485/ijst%2F2010%2Fv3i12%2F29846